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The evolutionary interplay between myxoma virus (MYXV) and the European rabbit (Oryctolagus cuniculus) following release
of the virus in Australia in 1950 as a biological control is a classic example of host-pathogen coevolution.We present a detailed
genomic and phylogeographic analysis of 30 strains of MYXV, including the Australian progenitor strain Standard Laboratory
Strain (SLS), 24 Australian viruses isolated from 1951 to 1999, and three isolates from the early radiation in Britain from 1954
and 1955. We show that in Australia MYXV has spread rapidly on a spatial scale, with multiple lineages cocirculating within in-
dividual localities, and that both highly virulent and attenuated viruses were still present in the field through the 1990s. In addi-
tion, the detection of closely related virus lineages at sites 1,000 km apart suggests that MYXVmoves freely in geographic space,
with mosquitoes, fleas, and rabbit migration all providing means of transport. Strikingly, despite multiple introductions, all
modern viruses appear to be ultimately derived from the original introductions of SLS. The rapidity of MYXV evolution was also
apparent at the genomic scale, with gene duplications documented in a number of viruses. Duplication of potential virulence
genes may be important in increasing the expression of virulence proteins and provides the basis for the evolution of novel func-
tions. Mutations leading to loss of open reading frames were surprisingly frequent and in some cases may explain attenuation,
but no commonmutations that correlated with virulence or attenuation were identified.
The experimental introduction of myxoma virus (MYXV) intothe European rabbit (Oryctolagus cuniculus) population of
Australia and its unprecedented and unanticipated spread initi-
ated one of the great natural experiments in evolution (1). The
subsequent emergence of slightly attenuated viruses that were
more efficiently transmitted and the natural selection of rabbits
with genetic resistance to MYXV were carefully documented in
real time (2). Sixty years later these studies continue to inform
theory and practice in host-parasite coevolution and particularly
the complex relationship between virulence and transmissibility.
MYXV is a poxvirus and the type species of the Leporipoxvirus
genus. MYXV is native to South America, where its natural host is
the tapeti (forest rabbit; Sylvilagus brasiliensis), in which the virus
causes a largely innocuous, localized, cutaneous fibroma. MYXV
is transmitted by mosquitoes or other biting arthropods probing
through the fibroma and picking up virus on their mouthparts.
Transmission is passive, asMYXV does not replicate in the vector.
In European rabbits, which are not native to the Americas,MYXV
causes the generalized lethal disease myxomatosis. As such, this
represents a classic example of a pathogen that is highly viru-
lent in a new host species with no evolutionary history of ad-
aptation to that pathogen. Viruses closely related to MYXV are
found in Sylvilagus bachmani (brush rabbit) on the west coast
of the United States and the Baja Peninsula of Mexico (Califor-
nian myxoma viruses) and in Sylvilagus floridanus (eastern cot-
tontail) in eastern and central parts of North America (rabbit
fibroma virus [RFV]) (2).
European rabbits were introduced into Australia with Euro-
pean settlement in 1788, but the continent-wide spread of rabbits
was initiated in 1859 by the introduction of 18 to 24 wild rabbits
for hunting.Within 50 years these rabbits had spread overmost of
Australia with the exception of the wet tropics and the far north
(3). The European rabbit becameAustralia’s worst vertebrate pest,
responsible for enormous ecological destruction and agricultural
losses. Field trials in 1950 to assess MYXV as a biological control
resulted in the mosquito-driven epizootic spread of the virus
throughout much of southeastern Australia in the summer of
1950 to 1951, and it reemerged the following spring (4). Assisted
by large-scale inoculation campaigns, MYXV spread and was es-
tablished over the rabbit-infested areas of Australia during the
next 5 years (2).
The MYXV introduced into Australia, termed Standard Labo-
ratory Strain (SLS), was derived from an isolate made in Brazil,
probably in 1910 (2, 5) and subsequently maintained by rabbit
passage. Importantly, the original virus used to initiate the
epizootic was available to serve as a reference for subsequent field
isolates. SLS had a case fatality rate estimated at 99.8% in infected
wild rabbits and similar lethality in laboratory rabbits, which are
domestic breeds of Oryctolagus cuniculus.
It quickly became apparent that viruses with slightly lower case
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fatality rates were emerging in the field and outcompeting ongo-
ing releases of the virulent SLS (6–8). Fenner and Marshall (9)
classified the virulence of MYXV into 5 grades based on average
survival times, case fatality rates, and symptomatology of groups
of 4 to 6 laboratory rabbits infected with very low doses of virus.
The predominant viruses in the field were of grade 3 virulence
(case fatality rates of 70 to 95%), with average survival times that
were prolonged compared to that for SLS (17 to 28 days versus
13 days). Mosquito transmission is a function of the titers of
virus in the skin lesions induced by the virus and how long the
rabbit survives. By allowing the infected rabbit to survive for lon-
ger with high titers of virus, themoderately attenuated viruses had
a selection advantage over more-virulent strains. Highly attenu-
ated grade 5 viruses (50% case fatality rates) tended to be poorly
transmitted because the infected rabbits controlled virus replica-
tion, in turn reducing transmissibility (10). Importantly, the
emergence of more-attenuated virus strains may have facilitated
the rapid selection of rabbits with genetic resistance toMYXV (2).
A separate strain of MYXV was released in France in 1952; the
virus was obtained from the Laboratory of Bacteriology in Laus-
anne, Switzerland, and has hence been termed the Lausanne strain
(Lu), although like SLS it was originally isolated in Brazil (in
Campinas in 1949). Unlike SLS, Lu had undergone relatively few
rabbit passages. Lu and SLS have indistinguishable levels of viru-
lence in laboratory rabbits; however, Lu is considerably more vir-
ulent than SLS in genetically resistant rabbits. Despite the differ-
ences in starting virus, environmental conditions, and insect
vectors, the outcome of MYXV-rabbit coevolution in Europe was
remarkably similar to that in Australia, with the emergence of
attenuated viruses and the selection of rabbits with genetic resis-
tance (11).
The Lu strain of MYXV is considered the reference genome.
It has a double-stranded DNA (dsDNA) genome of 161,777 bp
with inverted terminal repeats (TIR) of 11,577 bp. It contains
158 unique open reading frames, 12 of which are duplicated in
the TIR. Genes located toward the center of the genome tend to
be conserved between poxviruses and are essential for replica-
tion and structure, whereas those toward the termini tend to be
involved in subversion of the host immune response or have
host range functions and are less conserved across poxviruses
(12).
We have recently outlined the evolutionary patterns and dy-
namics of the Australian progenitor SLS virus and 19 Australian
isolates sampled between 1951 to 1999, as well as two isolates of
grade 1 and grade 5 virulence from the early radiation ofMYXV in
theUnitedKingdom following the introduction ofMYXV there in
1953 (13). To reveal the genetic basis for the phenotypic differ-
ences between these viruses, and particularly their profound dif-
ferences in virulence, we report here the detailed genome se-
quences of these viruses plus those of an additional five Australian
viruses. In addition, we sequenced and analyzed a second strain of
KM13 (KM13 2A) and the Lu virus strain produced by the Com-
monwealth Serum Laboratories (CSL) for release in Australia, as
well as a grade 3 virus isolated in the United Kingdom in 1954.
Such a rich genomic data set enabled us to obtain a more detailed
picture of the evolution and geographic spread of this virus
through Australia and particularly the broad range of genes in-
volved in this evolutionary process.
Materials and Methods
Virus isolates. The isolates of MYXV used in this study are described in
Table 1.
Preparation of DNA. Viruses were passaged twice in RK13 cells to
prepare working stocks; viral DNAwas prepared from infected RK13 cells
as previously described (13).
Sequencing, assembly, and comparative analyses. The seven virus
samples newly reported here were sequenced on the Illumina HiSeq 2000
platform. Demultiplexed and trimmed sequence reads were assembled
with the Velvet de novo assembler (14) using a range of k-mer values from
59 to 77 and an expected coverage of 600. Contigs containing MYXV
genomicDNAwere identified by BLASTX searches andwere ordered into
a single scaffold against the Lu genome (accession no. AF170726) using
the Abacas.pl script (15). The quality of each scaffold was verified by
remapping the untrimmed reads to the assembly using Smalt (www
.sanger.ac.uk/resources/software/smalt/); the resulting BAM files were
converted to pileup format to verify the read coverage at each site. Read
coverage line plots for scaffolds at each k-mer value were generated in R
and examined by eye. In general, we found that scaffolds generated at high
k-mers (greater than 65) resulted in single contig assemblies of theMYXV
genomes, but inspection of coverage plots revealed many low-coverage
regions. Further examination of these low-coverage areas revealed that
these were large insertions unique to the strain in question compared to
the 23 previously sequenced strains of MYXV (13). Assemblies at lower
k-mer values (51 to 65) were often fragmented into multiple contigs but
showed even read coverage across contigs corresponding to MYXV seg-
ments. Further, these were of the expected lengths relative to the 23 pre-
viously sequenced strains (13). Gaps, single nucleotide polymorphisms
(SNPs), and indels of interest were closed by Sanger sequencing of PCR
products. In every case, only one complete, or nearly complete, copy of the
terminal inverted repeat (TIR)was assembled at either the 5= or the 3= end,
though up to a full read length of the complementary TIR was observed at
the opposite end, allowing easy identification of the TIR junction. To
further verify the position of the TIR junction, we duplicated the complete
TIR, generated a reverse complement of the sequence that was added on
the opposite end, and remapped the sequence reads to that assembled
portion of the genome.
Genome annotation was transferred from the Lu strain to the newly
sequenced MYXV genomes using the Rapid Annotation Transfer Tool
(16). EMBL flat files of transferred gene models were then inspected and
compared to Luusing theArtemis comparison tool (17); incorrectmodels
were corrected, and new gene models were added where transfer had not
occurred. Genes are numbered based on their location in the MYXV ge-
nome, with the direction of transcription indicated by L or R (e.g.,
M010L). Genes in the TIR are identified by L/R (e.g.,M007L/R). Proteins
are identified by the same number as the gene with the transcription
direction omitted, e.g., M010.
To generate the heatmaps for the comparative analyses of each gene to
the SLS and Lu strains, we used a custom Perl script to produce multi-
FASTA files containing all taxa in which this gene was present. Sequence
alignments were generated using ClustalW (18), and PAUP* 4.0b10 (19)
was used to remove ambiguous and gapped sites from the alignments and
generate the number of SNP mutations in each gene. Columns from the
distance matrix comparing viral taxa to SLS were parsed, and two subse-
quent matrices were generated, one for European strains compared to Lu
and one for Australian strains compared to SLS.
Evolutionary analysis.A total of 30 genome sequences ofMYXVwere
subjected to phylogenetic analysis, with a total alignment length of
163,555 nucleotides (nt). Sequences were aligned by MAFFT (20), then
inspected by eye. Phylogenetic analysis employed the maximum likeli-
hood (ML) method, available in PhyML 3.0 (21). Because of the very low
numbers of substitutions separating these sequences, we employed the
HKY85 model of nucleotide substitution (22) with subtree pruning and
regrafting (SPR) branch swapping. To assess the robustness of each node
on the tree, a bootstrap resampling analysis was undertaken (1,000 repli-
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cates) employing the parameters described above. To determine whether
these 30 MYXV genomes contain any recombinant regions, we utilized
the RDP, GENECOV, and BOOTSCAN methods available within the
RDP4 package (23) and the default parameters. As with our previous
study (13), no recombination was observed.
To estimate the rates of evolutionary change and times to common
ancestry in these data (including those of two key nodes shown in Fig. 1),
we employed the BayesianMarkov chainMonte Carlo (MCMC)method,
available in the BEAST package (24). This analysis utilized both strict and
relaxed (uncorrelated log normal) molecular clocks, a Bayesian skyline
coalescent prior, and the HKY85 nucleotide substitution mode. The
MCMC was run for 100 million generations, and convergence was ob-
served in all parameters. Statistical uncertainly is presented as values for
the 95% highest-probability density (HPD).
Nucleotide sequence accession numbers. The seven new MYXV ge-
nome assemblies have been deposited onGenBank under accession num-
bers KC660079 to KC660085.
RESULTS
Evolution and phylogeography of MYXV. Our phylogenetic
analysis of 30 complete MYXV genomes, including 5 new Austra-
lian isolates sampled during 1993 to 1999 and an early attenuated
isolate from the United Kingdom sampled in 1954, depicted the
major division between the Australian and European epidemics
observed previously (Fig. 1) (13), with no evidence of recombina-
tion. In addition, that all the recently sampled Australian viruses
(1991 to 1999) are clearly distinct from both SLS and Lu indicates
that these two virusesmade no significant contribution to the later
evolution of MYXV in Australia even though they were intro-
duced multiple times over many years. Hence, these data suggest
that all (sampled) Australian MYXV strains have their ancestry in
the initial introduction of SLS in 1950, although the close phylo-
genetic relationship among the sequences means that we cannot
determine whether the Glenfield (Gv) strain, which was also
widely released in NSW and Victoria, made any contribution to
the spread of MYXV. Our estimates of rates of nucleotide substi-
tution—at 0.8 105 to 1.1 105 nucleotide substitutions per
site per year (95% HPD values)—and times to common ancestry
were also essentially identical to those observed previously (13).
Hence, these data again indicate that the evolution of MYXV is
both relatively rapid (for a dsDNA virus) and remarkably clock-
like.
A visual overview of genome scale genetic variation, manifest
as the genetic distance of each gene from the progenitor strain—
SLS for the Australian isolates and Lu for the European iso-
lates—is represented by heat maps (Fig. 2A and B, respectively).
These maps reveal that the majority of genes remain highly con-
served, with a few genes exhibiting more diversity. An example of
the latter is M017L. Although the function of this gene is un-
known, it has acquiredmutations in themajority of the Australian
strains compared to SLS (Fig. 2A; Table 2). Multiple genes
(M003.1L/R, M103L, M105L, and M132L) have acquired muta-
tions in OB3/1120/1996 andWS6/1071/1995, which are linked to
the other MYXV strains by a relatively long branch (Fig. 1). How-
ever, of these, only M103L encodes a protein with a predicted
function (structural membrane protein), while the majority of
TABLE 1 Origin of strains of MYXV sequenced heree and in reference 13
Virus Formal name Geographic origin Source Reference
Virulence
grade Region sequencedd
Accession
no.
SLS (Moses strain/strain B) None given Brazil Rabbit tissue stock (Fenner)a 9 1 1–161777 (161,763) JX565574
Glenfield Aust/Dubbo/2-51/1 Central NSW CV-1 cell stockb 29 1 15–161763 (161,742) JX565567
KM13 Aust/Corowa/12-52/2 Southern NSW Rabbit tissue stock (Fenner) 9 3 1–161777 (161,771) JX565569
KM13 2A Aust/Corowa/12-52/2A Southern NSW Rabbit tissue stock (Fenner) 30 3 1–161777 (161,769) KC660080
Uriarra Aust/Uriarra/2-53/1 Canberra District CV-1 cell stock 29 5 1–161777 (161,768) JX565577
SWH Aust/Southwell Hill/9-92/1 Canberra District Wild rabbit 31 4 1–161777 (161,797) JX565576
BRK Aust/Brooklands/4-93 Canberra District Wild rabbit 31 1 1–161777 (161,701) JX565562
Bendigo Aust/Bendigo/7-92 Central Victoria Wild rabbit 31 1 1–161777 (161,738) JX565565
Meby Aust/Meby/8-91 Tasmania Wild rabbit 31 5 87–161691 (161,542) JX565571
Lu Brazil/Campinas/1949/1 Brazil Commonwealth Serum
Laboratories 1973c
1 1–161777 (161,778) JX565570
Cornwall England/Cornwall/4-54/1 Cornwall, UK Rabbit tissue stock (Fenner) 9 1 1–161777 (161,775) JX565566
Sussex England/Sussex/9-54/1 Sussex, UK Rabbit tissue stock (Fenner) 9 3 1–161777 (161,778) KC660084
Nottingham attenuated England/Nottingham/4-55/1 Nottingham, UK Rabbit tissue stock (Fenner) 9 5 1–161777 (161,777) JX565572
Gung/91 Aust/Gungahlin/1-91 Canberra District Wild rabbit 31 4 151–161627 (161,443) JX565568
Wellington Aust/Wellington/1-91 Central NSW Wild rabbit 31 1 29–161749 (161,688) JX565582
BRK/12-2-93 Aust/Brooklands/2-93 Canberra District Wild rabbit 25 NDf 140–161638 (161,496) JX565563
BD23 Aust/Bulloo Downs/11-99 Southwest Queensland Wild rabbit 49 ND 285–161555 (161,971) JX565584
BD44 Aust/Bulloo Downs/12-99 Southwest Queensland Wild rabbit 49 ND 1–161777 (162,847) KC660079
BRK/897 Aust/Brooklands/1-95 Canberra District Wild rabbit 25 ND 103–161675 (161,545) JX565564
OB1/406 Aust/OB1/Hall/3-94 Canberra District Wild rabbit 25 ND 87–161691 (161,612) JX565573
OB2/W60 Aust/OB2/Hall/11-95 Canberra District Wild rabbit 25 ND 1–161777 (162,483) KC660081
OB3/Y317 Aust/OB3/Hall/2-94 Canberra District Wild rabbit 25 ND 1–161777 (161,748) KC660083
OB3/1120 Aust/OB3/Hall/2-96 Canberra District Wild rabbit 25 ND 1–161777 (161,722) KC660082
WS1/234 Australia/Woodstock 1/3-94 Canberra District Wild rabbit 25 ND 1–161777 (161,754) JX565578
WS6/1071 Aust/Woodstock 6/11-95 Canberra District Wild rabbit 25 ND 41–161737 (161,752) JX565580
WS1/328 Aust/Woodstock 1/3-94 Canberra District Wild rabbit 25 ND 156–161622 (161,483) JX565579
WS6/346 Aust/Woodstock 6/3-95 Canberra District Wild rabbit 25 ND 140–161638 (161,430) JX565581
SWH/8-2-93 Aust/Southwell Hill/2-93 Canberra District Wild rabbit 25 ND 1–161777 (161,740) JX565575
SWH/805 Aust/Southwell Hill/11-93 Canberra District Wild rabbit 25 ND 1–161777 (161,780) KC660085
SWH/1209 Aust/Southwell Hill/2-96 Canberra District Wild rabbit 25 ND 33–161745 (162,413) JX565583
a Virus stocks were originally obtained as freeze-dried rabbit tissue from Frank Fenner, John Curtin School of Medical Research, Australian National University, Canberra, ACT,
Australia.
b Virus stocks were from viruses plaque purified as described in reference 29.
c Virus was from an ampoule of freeze-dried rabbit tissue powder prepared by the Commonwealth Serum Laboratories for rabbit control.
d Based on the Lu sequence from Cameron et al. (12), 1 to 161777, as corrected by Morales et al. (34); the actual sequence length is shown in parentheses.
e Boldface indicates data for isolates sequenced for this paper.
f ND, not determined.
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mutations involved are commonplace and/or synonymous ones
exhibiting no clear association with changing virulence. Similarly,
with the exception of the attenuated Spanish isolate 6918, which
appears as genetically distant based on this and the phylogenetic
analyses, the European isolates have very fewmutations compared
to Lu (Fig. 2B), reflecting their sampling early in the epidemic.
To reveal aspects of the phylogeography of MYXV, we coded
the Australian isolates by their state of origin (Fig. 1), in which CD
delineates viruses that were sampled in close proximity to each
other (within 10 to 15 km) in the Canberra District, which strad-
dles the NSW/Australian Capital Territory (ACT) border in
southeastern Australia (see below). Strikingly, BD23 and BD44,
sampled from hot, dry rangelands at Bulloo Downs in southwest
Queensland in 1999, are very closely related to viruses (OB2/W60/
1995 and SWH/1209/1996) sampled 3 to 4 years earlier from the
cool-climate, higher-rainfall Canberra district, approximately
1,000 km away. Also of interest is the Meby strain, sampled from
Tasmania, which is separated frommainlandAustralia by the Bass
Strait, which is up to 240 km wide. Although SLS was released in
Tasmania in the early 1950s following its spread on the mainland,
Meby is clearly descended from a mainland virus that diverged in
the late 1960s and has then remained isolated since this time (Fig.
1). It is therefore possible that the virus reached Tasmania from
the mainland on a mosquito inadvertently transported by ship or
plane. The majority of the sequenced viruses were isolated be-
tween 1993 and 1996 from a set of seven closely situated study sites
(WS1, WS6, OB1, OB2, OB3, SWH, and BRK) in the Canberra
district (25, 26). From the phylogenetic analysis (Fig. 1) it is obvi-
ous that viral lineages have cocirculated at a single locality during
a specific time period. In general, these results highlight the rela-
tive rapidity ofMYXVmovement, likely aided bymosquito trans-
mission, including a dispersal of over 1,000 km during 1950.
Comparison of the SLS and Lu sequences. SLS was the origi-
nal virus released in Australia in 1950.We compared the complete
genome sequence of SLS to that of the Lu strain. These two pro-
genitor strains have differences in symptomatology, virulence,
1.0E-4 subs/site
Nott_Attenuated/1955
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SWH/805/1993* (CD)
Gung/1991 (CD)
BRK/1993 (CD)
Uriarra/1953 (ACT)
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SWH/9/1992 (CD)
OB2/W60/1995* (CD)
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OB3/Y317/1994* (CD)
OB1/406/1994 (CD)
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SWH/8-2-93/1993 (CD)
MYXV/6918/1995
BD23/1999 (QLD)
Bendigo/1992 (VIC)
BRK/12-2-93/1993 (CD)
KM13/1952 (NSW)
SWH/1209/1996 (CD)
BD44/1999* (QLD)
OB3/1120/1996* (CD)
Wellington/1991 (NSW)
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M029L
A17V
M029L
V17A
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M156R
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FIG 1 Phylogeny and phylogeography of MYXV isolates. Samples are color-coded according to place of sampling (BRK [Brooklands], green; OB, pink, SWH
[Southwell Hill], red; WS [Woodstock], blue), while the state or region of sampling is noted in parentheses (ACT, Australian Capital Territory; CD, Canberra
District; NSW,New SouthWales; QLD,Queensland; TA, Tasmania; VIC, Victoria). Viruses newly sequenced here aremarkedwith an asterisk. The phylogenetic
distribution of mutation and reversion in the M029L gene and of mutation in the M156R gene is also shown. Bootstrap values are shown for key nodes, and all
horizontal branches are drawn according to the number of nucleotide substitutions per year. Divergence times (95% HPD values) for two key nodes in the
Australian part of the phylogeny were inferred from the BEAST analysis (see Materials and Methods).
Genome Scale Evolution of Myxoma Virus
December 2013 Volume 87 Number 23 jvi.asm.org 12903
 o
n
 M
arch 12, 2015 by Australian National Univ.
http://jvi.asm.org/
D
ow
nloaded from
 
and passage history prior to release. Overall, there are 80 nucleo-
tide differences (0.05% difference), including indels, between SLS
and Lu (72 if TIRs are counted in only one copy) (Table 3). How-
ever, frameshifts in M005L/R, M083L, and M152R due to indels
also producemultiple amino acid changes in SLS compared to the
Lu sequence: M005L/R, which codes for an E3 ubiquitin (Ub)
ligase/apoptosis regulator, is disrupted by a C insert at nucleotide
34. It is likely that translation occurs from an alternative ATG
from nucleotide 17 that does not change the ANK repeats and the
C-terminal F-box domain of the M005 protein. M083L is dis-
rupted by a C deletion in a homopolymer tract at nucleotide 513.
M083 is homologous to rabbit carbonic anhydrase (12) and is
probably a virion structural protein. Finally, there is a T deletion
in a homopolymer toward the 3= end of the M152R (Serp 3) gene
at nucleotide 782; read-through of the Lu stop codon leads to a
predicted protein of 273 amino acids in SLS rather than 266 amino
acids in Lu. These indels are also present in Australian isolates of
MYXV sampled between 1951 and 1953, confirming that the mu-
tations were present in the progenitor virus. It is likely that one of
these frameshift mutations explains the reduced virulence of SLS
compared to that of Lu.
Comparisonsof SLSwith subsequentAustralian isolates.We
sequenced three isolates of MYXV that had been sampled within
the first 3 years of the initial epizootic ofmyxomatosis in Australia
and that had been previously characterized in terms of virulence
(9): the Gv strain (Dubbo/Feb 1951; grade 1 virulence), KM13
(Corowa/Dec 1952; the prototype grade 3 virus), andUriarra (Ur)
(Uriarra/Feb 1953; grade 5 virulence [27]). Amino acid sequence
changes and gene disruptions between SLS and these three viruses
are summarized in Table 4.
Three of the nonsynonymous mutations in Gv, which is more
virulent than SLS, are in enzymes involved in viral transcription
and replication, M044 (RNA helicase: R606H; the R is conserved
in chordopoxvirus sequences), M108 (DNA helicase: F18I; only
MYXV and RFV have F at this position; other chordopoxviruses
have I, M, or L), and M114 (RNA polymerase: A686V; the A is
completely conserved at this position in chordopoxvirus se-
quences), each ofwhich could affect replication efficiency.M014L,
M130R, and M153R all have single-nucleotide indels that disrupt
the reading frame. The single-nucleotide indel in M014L causes
premature termination at residue 477, making the protein smaller
than the 517-amino-acid SLS protein. This indel is also present in
Ur and KM13, indicating that the mutation arose early on. M014
has an N-terminal BTB motif and C-terminal kelch motifs and is
predicted to form an E3 ubiquitin ligase complex that targets cel-
lular proteins to the proteosome for destruction (28). This trun-
FIG 2 Heat maps showing the number of SNPmutations in each gene from the SLS (A) and Lu (B) strains. Genes are organized in rows according to their order
in the reference genome, and taxa are ordered along columns by their branching order in the MYXV phylogeny.
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cation would delete the final kelch domain, potentially altering
target protein recognition.However, the role ofM014 in virulence
is unknown, as is that of M130R. The large number of gene dis-
ruptions in Gv suggests that this virus may be a variant selected
during previous plaque purification (29) from which this virus
was obtained. The likely explanation for the attenuation of KM13
is the disruption toM014L. Although this mutation is also present
in the virulent Gv, there is no other obvious mutation that might
lead to the attenuation ofKM13. To further assist in the documen-
tation of virulence determinants, we also sequenced a laboratory
variant of KM13 reported to have a lower case fatality rate (KM13
2A) (2, 30). The only difference between KM13 and KM13 2A
appears to be an extra A in a noncoding sequence of KM13.
Also of note is that Ur has an extra C inserted after nucleotide
TABLE 2 Mutations from SLS conserved in Australian MYXV isolatesa
SLS position Genek Protein functione Mutation No. of viruses
1968 M002L/R TNF binding/apoptosis inhibition A226V 21 (all recent)
2576 M002L/R TNF binding/apoptosis inhibition Synonymous GCG¡GCA 24 (all Australian)
3168 M003.1L/R PRRe signal inhibition? A37V 21 (all recent)
5082 M005L/R Apoptosis inhibition/Ub ligase R434W 21 (all recent)
5756 M005L/R Apoptosis inhibition/Ub ligase S209Y 21 (all recent)
11484 Intergenic — A¡G 13
12348 M009L Putative Ub ligase A261V 16b
12715 M009L Putative Ub ligase Frameshift T insert 420 20 (including Meby)c
16042 M014L Putative Ub ligase V175I 21 (all recent)
16201 M014L Putative Ub ligase G122W 21 (all recent)
16478 M014L Putative Ub ligase Synonymous GTC¡GTT 18
16615 Intergenic — A deletion 13 (includes Ur)
16923 M015L Ribonucleotide reductase Synonymous GAA¡GAG 21 (all recent)
17332 M015L Ribonucleotide reductase V85A 21 (all recent)
17877 M017L ? E71K 21 (all recent)
18236 Intergenic — Multiple GTAGGTAG insert 21
18250 Intergenic — Multiple AGTTTAGT insert 17
18277 Intergenic — T¡C 21 (all recent)
21578 M021L EV maturation; VACF12L orthologue D315N 14
23608 M022L EVg protein Synonymous GTC¡GTT 21 (all recent)
24933 M025L VACV F16 orthologue M11I 20
28185 M028L EV formation S244L 18
36832 M034L DNA polymerase Synonymous TTC¡TTT 21 (all recent)
38437 M036L VACV O1 orthologue C270Y 22 (all recent and KM13)
38987 M036L VACV O1 orthologue Synonymous CTG¡TTG 21 (all recent)
41406 Intergenic — T insert 20
47167 M045L Virion morphogenesis D263N 21 (all recent)
50515 M049R VACV G5 orthologue Synonymous CTG¡TTG 21 (all recent)
52256 M052L Core structural protein S29N 21 (all recent)
55900 M057L Core protein L90V 21 (all recent)
57398 M060R Virion protein Synonymous GCG¡GCA 21 (all recent)
58821 M062R Host range K142T 20
59512 M063R Host range S195C 21 (all recent)
59585 Intergenic — T deletion 20
60567 M065R Poly(A) poli subunit T98 M 21 (all recent)
64305 M068R RNA pol subunit Synonymous ACG¡ACA 22
70115 M072L RNA pol-associated transcription factor I150T 22
82120 M083L CA homologue/virion protein G insert 21 (all recent)
85496 M086L DNA helicase Synonymous CGA¡CGG 21 (all recent)
99168 M099L Core protein precursor Synonymous GCG¡GCA 20
112683 M114R RNA pol subunit P1147H 12
115902 M121R CLECTh EV protein S21F 20
119939 M127L Photolyase Synonymous 1107 AGC¡AGT 15
123409 M132L ? C133Y 18
125935 M134R Membrane protein S84P 21 (all recent)
128748 M134R Membrane protein Synonymous GCG¡GCA 21 (all recent)
131595 M134R Membrane protein AAA insert (K) 22
133151 M137R VACV A51 orthologue Synonymous GGC¡GGT 20
135593 M140R Putative Ub ligase P76H 24
142764 M148R Putative Ub ligase L383F 21 (all recent)
145699 M150R Putative Ub ligase P173S 21 (all recent)
147192 M151R Serpin (Serp 2) R173G 21 (all recent)
148711 M153R Ub ligase MHC-1 downregulation Synonymous TGT¡TGC 17
149127 M153R Ub ligase MHC-1 downregulation L204S 19 (24) (all Australian)d
149717 M154R VACVM2 orthologue/NF-B inhibition? Y53C 19
149836 M154L VACVM2 orthologue/NF-B inhibition? Synonymous 39 GTC¡GTT 13
150280 M156R eIF2 homologue (IFN resistance) L98P 13
a Mutations shared by 12 or more viruses.
b SWH/1209, OB3/1120, BD44, and BD23 have deletions of the associated region of M009L.
c Meby was isolated in Tasmania not on mainland Australia. All other Australian isolates were from the mainland. There are 21 isolates from 1991 to 1999.
d All Australian isolates sequenced have the nucleotide mutation at SLS 149127, but Gv, WS6/1071, BD44, and Meby have frameshift mutations that alter the reading frame of
M153R and Wellington has a 9-nucleotide deletion which shifts the amino acid mutation to L201S.
e ?, unknown; —, not applicable.
f PRR, pattern recognition receptor.
g EV, enveloped virus.
h CLECT, C-type lectin.
i pol, polymerase.
k Mutations duplicated in TIR are indicated by L/R in the gene name and are only shown at the LH end of the genome.
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30 in M005L/R. This means that the alternative ATG, which we
predict to be used by SLS and all other Australian viruses se-
quenced here, does not create a sense open reading frame (ORF)
in Ur. The only downstream ATG that is compatible with an ORF
is at nt 308; translation from this ATG would produce a 382-
residue protein with 5 ANK repeats and the C-terminal F-box
compared to 7 ANK repeats in the 478-residue SLS protein. How-
ever, there is no convincing promoter sequence upstream of this
ATG. This is likely the main attenuating mutation in Ur. Ur also
has an A insert in a homopolymer tract toward the 3= end of
M134R at nucleotide 5911, the same location as the 3A insert inGv
andKM13 (Table 4). This leads to a predicted truncated protein of
1,973 amino acid residues, rather than the 2,000 residues of the
SLS and Lu proteins, which retains the predicted C-terminal
transmembrane domain that is conserved across the Chordopox-
virinae.
TABLE 3 Genome changes in SLS compared to Lua
Lu position Lu sequence
SLS
sequence
SLS
position Gene Mutation and/or location Protein function
22 A —b 21 Noncoding
621 A C 621 Noncoding
2577 C T 2577 M002L Sync GCG¡GCA (A) nt 69 TNF binding/apoptosis regulator
2794 G — 2793 Intergenic Bwd M003.1 and M002
6092 C T 6091 M005L D98N GAC¡AAC nt 297 E3 Ub ligase/apoptosis regulator
6349 — G 6349 M005L Frameshift E3 Ub ligase/apoptosis regulator
6351 A G 6351 M005L Syn CCT¡CCC (P) nt 34 E3 Ub ligase/apoptosis regulator
9370 G A 9370 M008L Syn GAC¡GAT (D) nt 1005 Putative E3 Ub ligase
13169 G T 13169 Intergenic Bw M009L and M10L
18237–18244 GGTATGTA — 18235 Intergenic Bw 17L and 18L tandem repeat
20976 C T 20967 M021L Syn CAG¡CAA (Q) nt 1554 EV maturation
22645 C T 22636 M022L Syn ACG¡ACA (T) nt 1032 EV protein
25039 G A 25030 M026R A9T GCA¡ACA nt 25 DNA binding phosphoprotein
30013 T C 30004 M030L T10A ACA¡GCA nt 28 RNA pol subunit
36188 T C 36179 M034L Y227C TAT¡TGT nt 680 DNA pol
38319 G A 38310 M036L Syn TTC¡TTT (F) nt 936 VACV O1L orthologue
40605–40607 TTC — 40595 M040L E 258 deleted DNA binding phosphoprotein
48097 G A 48085 M046L Syn CCC¡CCT (P) nt 201 Membrane protein
48780 A G 48768 M047R T164A ACA¡GCA nt 490 Late gene expression regulator
53704 T C 53692 M054R Syn CGT¡CGC (R) nt 519 Membrane fusion complex
54952 A G 54940 Intergenic Immediately 5= to M056R
55308 C T 55296 M057L S291N AGT¡AAT nt 872 Core protein
56431 C T 56419 M058R Syn ATC¡ATT(I) nt 228 Core protein
57922 A T 57910 M061R K41N AAA¡AAT (K) nt 123 Thymidine kinase
60376 A G 60364 M065R Syn ACA¡ACG (T) nt 90 Poly(A) pol regulatory subunit
62205 — T 62194 Intergenic Immediately 5= to M068R
67449 C T 67438 M071L Syn TCG¡TCA (S) nt 735 Membrane protein
74445 G A 74434 M076R Syn TCG¡TCA (S) nt 1740 mRNA capping enzyme
80489 A G 80478 M081R Q371R CAG¡CGG nt 1112 Early transcription factor subunit
82131 G — 82119 M083L C deletion at 513¡reading frameshift Carbonic anhydrase homology/membrane protein
82179 C T 82167 M083L Syn CTG¡CTA (L) nt 462 Carbonic anhydrase homology/membrane protein
83974 A G 83962 M085R Syn GTA¡GTG (V) nt 669 VACV D10R orthologue
87056 A C 87044 M088L Syn TCT¡TCG (S) nt 1494 Virion protein
90140 T C 90128 M092L Syn GCA¡GCG (A) nt 1790 Core protein
118290 T C 118278 M124R Syn GGT¡GGC (G) nt774 Unknown
123774 T C 123762 M132L Syn GTA¡GTG (V) nt 45 Unknown
128789 C T 128777 M134R S1031L TCG¡TTG nt 3092 Membrane protein
129085 G T 129073 M134R A1130S GCT¡TCT nt 3388 Membrane protein
130326 C T 130314 M134R Syn GGC¡GGT (G) nt 4629 Membrane protein
131079 C T 131067 M134R Syn GAC¡GAT (D) nt 5382 Membrane protein
131133 T C 131121 M134R Syn GCG¡GCC (A) nt 5436 Membrane protein
131176 C T 131164 M134R Syn GTG¡TTG (L) nt 5479 Membrane protein
131187 C A 131175 M134R Syn ACC¡ACA (T) nt 5490 Membrane protein
131230 A G 131218 M134R T1845A ACG¡GCG nt 5533 Membrane protein
131238 G C 131226 M134R E1847D GAG¡GAC nt 5541 Membrane protein
131259 T C 131247 M134R Syn GAT¡GAC (D) nt 5562 Membrane protein
131316 A G 131304 M134R Syn GCA¡GCG (A) nt 5619 Membrane protein
131328 G A 131316 M134R Syn CCC¡CCA (P) nt 5631 Membrane protein
131377 A G 131365 M134R T1894A ACA¡GCA nt 5680 Membrane protein
131424 C T 131412 M134R Syn GAC¡GAT (D) nt 5727 Membrane protein
131487 G A 131475 M134R M1930I ATG¡ATA nt 5790 Membrane protein
131550 G A 131538 M134R Syn GGG¡GGA (G) nt 5853 Membrane protein
132122 G A 132110 M135R Syn GCG¡GCA (A) nt 420 Immune modulation/virulence
133197 G A 133185 M137R D96N GAC¡AAC nt 286 VACV A51
133552 A G 133540 M137R D214G GAC¡GGC nt 641 VACV A51
134435 C T 134423 M138L D106N GAC¡AAC nt 316 -2,3-Sialyltransferase
141046 T C 141034 M147R S115P TCG¡CCG nt 3343 S/T-specific protein kinase
147887 G A 147875 M152R A66T GCA¡ACA nt 196 Serp 3
148316 A G 148304 M152R T209A ACA¡GCA nt 625 Serp 3
148375 A G 148363 M152R Syn GCG¡GCA (A) nt 684 Serp 3
148472 T — 148459 M152R nt 782; readthrough Serp 3
149140 C T 149127 M153 S204L TCA¡TTA nt 611 E3 Ub ligase/MHC-1 downregulation
149864 C T 149851 M154L Syn GTG¡GTA (A) nt 24 NF-B regulation
a Mutations in the TIR are only shown at the left hand TIR.
b —, nucleotide deleted.
c Syn, synonymous.
d Bw, between.
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Recent Australian isolates. In total, we determined sequences
for 21 Australian viruses isolated between 1991 and 1999, 6 of
which had been characterized by virulence assays: Bendigo, Wel-
lington, BRK (grade 1), SWH,Gung (grade 4), andMeby (grade 5)
(31). All of these viruses have theC insertion at 35 inM005L/R and
the T deletion inM152R seen in SLS.However, the indel inM083L
present in SLS, Ur, Gv, and KM13 has reverted in every Australian
isolate sequenced from the 1990s. Similarly, the indel disrupting
theM014L gene found in Gv, Ur, and KM13 is not present in any
of the more recent isolates. All the isolates have the 3A indel in
M134R seen in Gv and KM13. However, the underlying sequence
reads that map to that genomic region indicate that there is a
subpopulation of viruses in OB3/1120 that have a 2A insertion,
rather than a 3A insertion; this 2A indel would lead to disruption
of the M134R ORF. A similar subpopulation with the 2A insert
was seen in Ur, which has a majority population with a single A
insert. Homopolymer sequences such as those inM134R are com-
mon in MYXV, and poly(A) or poly(T) tracts are common at the
3= ends of genes and in the intergenic sequence, where they are
frequently part of promoter structures for the downstreamgene or
the T5NT early transcription termination signal. In the Australian
isolates, 13 of 16 single-base indels that occur in coding sequences
(Table 5) occur in homopolymer tracts of 4 or more bases, and
there are 17 positions with single-base indels in intergenic ho-
mopolymers involving one or more viruses (positions in TIRs
have been counted only once). Polymerase slippage leading to
read-throughs or premature termination (e.g., SLS M152R) may
facilitate evolutionary plasticity, allowing slight changes in protein
sequences. Indels either in homopolymers or repeat sequence can
also lead to gene disruption, in turn affecting virulence (32, 33),
and also function to repair ORFs, as in the case for M083L.
All but one of the recent isolates have a frameshift mutation
due to a single nucleotide insertion in a homopolymer tract in
M009L, a member of a three-gene family (M006L/R, M008L/R,
andM009L) (12) that are predicted to encode E3 ubiquitin ligases
with N-terminal BTB domains followed by kelch motifs (28). The
insertion at nucleotide 420 produces a truncated protein of 146
rather than 509 residues. In addition, four viruses have further
mutations that disrupt the reading frame, and M009L is also dis-
rupted in viruses that have gene duplications from the right hand
(RH) end of the genome (see below), implying that this gene is
nonessential. BRK has a 92-bp deletion in theM036L gene, which
leads to a truncated protein of only 212 residues rather than 680 in
the SLS protein. The function of this gene (an orthologue of vac-
cinia virus [VACV]O1L) inMYXV is unknown, but in VACV the
O1 protein enhances signaling via Erk1/2 by the viral epidermal
growth factor (VGF) homologue and increases virulence (60). As
BRK is of grade 1 virulence (31),M036L is unlikely to be crucial for
virulence in this virus. In this respect, the attenuatedUnited King-
dom isolates Sussex (1954; grade 3) and Nottingham (1955; grade
5) also have a common indel that disrupts the M036L ORF, and
the attenuated Spanish isolate 6918 has an independent disrup-
tion in M036L (34). Both Nottingham and 6918 possess other
mutations that explain attenuation. However, the disruption in
M036L is the only one in Sussex, suggesting that it may play some
role in virulence.
ORF-disrupting mutations were also common in M153R,
which encodes a protein with an N-terminal RING-CH domain,
which is predicted to form an E3 Ub ligase complex and which
downregulates major histocompatibility complex class 1 (MHC-
1), CD4, ALCAM/CD166, and Fas/CD95 on the membranes of
infected cells, potentially inhibiting CD8 T lymphocyte recogni-
tion and death signaling. Deletion of this gene in the T1 Lu-de-
rived strain reduced the case fatality rate from 100% to 30% (35–
37). Meby, a grade 5 virus, has a 73-bp deletion between repeat
sequence blocks (AATACG) in the region ofM153R encoding the
C-terminal conserved region (CR) (31, 35) of the 206-amino-acid
protein, which leads to read-through of the normal stop signal and
a completely changed C-terminal protein sequence after residue
168. A single nucleotide deletion at nt 469 inWS6/1071 and OB3/
TABLE 4 Coding changes and indels in viruses from 1951 to 1953 compared to SLS
Gene Protein function (no. of aab)
Changea for virus:
Glenfield (1951, grade 1) KM13 (1952, grade 3) Ur (1953, grade 5)
M005L/R Host range/E3 Ub ligase (478) ORF disrupted by C nt
insc at 30
M014L E3 Ub ligase (517) ORF disrupted by C nt ins at 1405 ORF disrupted by C nt
ins at 1405
ORF disrupted by C nt
ins at 1405
M036L VACV O1 orthologue (680) C270Y* F293L
M044R RNA helicase (678) R606H
M071L Virion protein (324) E172K
M072L RNA pol-associated transcription
factor (796)
I150T*
M108R DNA helicase (478) F18I
M114R RNA pol subunit (1,155) A686V
M130R Unknown (122) ORF disrupted by G ins at 30 f
M134R Surface glycoprotein (2,000) AAA nt ins* K AAA ins* K A nt ins¡premature stop
at 1973
M137R Orthologue to VACV A51 (310) A308T
M140R E3 Ub ligase (553) P76H* P76H* P76H*
M141R OX-2 homologue (218) S45 insert
M153R RING CH E3 Ub ligase (206) ORF disrupted by G nt deletion at 329 L240S* L240S*
a , present in all modern isolates from Australia.
b aa, amino acids.
c ins, insert.
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1120 leads to a stop after residue 161 and removes the CR region
but retains the N-terminal RING-CH domain and two putative
transmembrane domains at 95 to 115 and 135 to 153 (35). Gv and
BD44 both have truncated proteins of 118 and 124 residues due to
an independent indel at nt 329. Other indels causing significant
disruption to ORFs were found only in single viruses: M000.5L/R
(BD44; unknown function), M008.1L/R (BD44; secreted serine
proteinase inhibitor; virulence function), M005L/R (WS6/346;
host range; virulence function), M012L (OB3/Y317; dUTPase),
and M147R (BD23; Ser/Thr-specific protein kinase) (Table 5).
The disruptions toM008.1L/R in BD44 andM005L/R inWS6/346
might be expected to attenuate these viruses (38, 39).
Gene duplications. The inverted terminal repeat regions of
poxviruses contain noncoding terminal regions essential for rep-
lication but also contain different numbers of genes, depending on
the location of the TIR boundary. These genes typically have vir-
ulence or host range functions, but the number of genes can vary
greatly. This region also appears to be a potential recombination
hot spot, as shown by recombination and deletions, including
those in malignant rabbit virus, a recombinant between MYXV
and RFV (40), or the MYXV SG33 vaccine strain (41).
Two genes, M154L and M156R, which are normally found as
single copies outside the RH TIR, with M156R overlapping the
TIR boundary, have been duplicated at the left hand (LH) TIR in
the common ancestor of SWH/1209, OB2/W60, BD44, and BD23.
In addition, theM153R gene has been partially duplicated (Fig. 3).
This duplication is essentially an expansion of the TIR by 1,635 bp,
36 nt downstream of the M153R ATG start codon, meaning that
M153R now overlaps the TIR junction (25). At the LH end of the
genome, this duplicated sequence has replaced 923 bp of the
M009L gene, leaving only the 5= 608 bp; however, theM009LORF
is disrupted after codon 146 due to a T insert at nt 420. M156 is an
orthologue of the VACVK3 protein and is predicted to inhibit the
action of type 1 interferon (IFN) (42). M154 is an orthologue of
VACV M2 and so may inhibit NF-B (12, 43). At the LH end,
M153R lacks the 5= 36 nucleotides and upstream promoter, and
TABLE 5 Insertion and deletions in coding regions of Australian MYXV isolates
SLS positiona Gene Protein function Mutation and contextc Effect
Virus(es) (virulence grade if
known)
408 M000.5L/R ?b G del Frameshift from aa 58 and read-
through stop codon
BD44
5533 M005L/R Apoptosis inhibition/host range C insert (homopol) Stop after aa 317 WS6/346
6352 M005L/R Apoptosis inhibition/host range C insert (homopol) ORF disruption Ur (5)
10663 M008.1L/R Serpin CC insert (homopol) ORF disruption BD44
11626 M009L Putative Ub ligase A del (homopol) ORF disruption SWH/8-2-93
12170 M009L Putative Ub ligase TA insert (TA repeat) ORF disruption BRK (1)
12715 M009L Putative Ub ligase A insert (homopol) ORF disruption All recent Australian strains
except Bendigo (1)
12809 M009L Putative Ub ligase A del ORF disruption WS6/1071, OB3/1120
14397 M012L dUTP pyrophosphatase 13 nt del ORF disruption OB3/Y317
15164 M014L Putative Ub ligase G insert (homopol) ORF disruption Gv (1), KM13 (3), Ur (5)
18324 M018L Cytoplasmic protein; VACV F8L
orthologue
TT insert Frameshift from aa 60; read-through
adds 20 aa
OB3/Y317
22511 M021L EV maturation; VACV F12L orthologue 9-nt insert (duplication) Duplicates LLG aa 4–6 OB3/Y317
38589–38680 M036L VACV O1 orthologue 92-base deletion ORF disruption BRK (1)
40596 M040L DNA binding phosphoprotein TCT duplication E258 inserted Bendigo (1)
58322 M061R Thymidine kinase T insert (homopol) Read-through adds LKY to C
terminus
WS1/234
59143 M063R Host range ACC duplication H72 duplicated Gung/91 (4)
59554–59568 M063R Host range 15 base del of repeat sequence Deletes TEEEE from a repeat at the
C terminus
WS6/346
60122–60124 M064R Host range? AGA del (tandem repeat) E deleted OB1/406; BRK/12-2-93
60122–60124 M064R Host range? AGA inserted (tandem repeat) E 168 inserted Well (1); WS1/234; BRK/
897; SWH/805;
OB3/Y317
82120 M083L CA homologue/structural G insert (homopol) Corrects G deletion in SLS All recent Australian strains
92163 M093L Core protein GGAAAC duplication VP duplication SWH (4)
113080 M115L Fusion protein CTTCGT del 66D 67E deleted Gung/91 (4)
122397 M130R ? G insert (homopol) ORF disrupted Gv (1)
131595 M134R Transmembrane protein AAA insert (homopol) K insert All Australian strains except
Ur (A) and SLS; OB3/
1120 has 2A
subpopulation
131595 M134R Transmembrane protein A insert (homopol) Truncates ORF, early stop Ur (5)
137195 M141R OX-2 homologue; downregulation of
macrophage activation
AGT insert (tandem repeats) S insert in repeat sequence Gv (1)
141092 M147R S/T-specific protein kinase GT del (tandem repeat) Repeat sequence disrupts ORF BD23
148485 M152R Serp 3 A del (homopol) Premature stop 271 (SLS 273) WS6/1071; OB3/1120
148845 M153R Ub ligase/MHC-1 downregulation G del (homopol) ORF disruption, early stop after aa
118
GV (1)
148845 M153R Ub ligase/MHC-1 downregulation G insert (homopol) ORF disruption, early stop after aa
124
BD44
148985 M153R Ub ligase/MHC-1 downregulation T del ORF disruption, stop after aa 161 WS6/1071; OB3/1120
149018 M153R Ub ligase/MHC-1 downregulation 73 bp del between repeats Sequence read-through replaces CR
domain of M153
Meby (5)
149062–149070 M153R Ub ligase/MHC-1 downregulation 9 bp del in duplicated sequence VEE repeat deleted from CR domain Well (1)
150294 M156R eIF2 homologue; IFN resistance T del (homopol) Read through stop, extra EG at C
terminus
WS6/346; OB3/Y317
a Sequence positions are for the Australian progenitor SLS; mutations in genes within the TIRs are shown only for the left-hand TIR.
b ?, unknown.
c del, deletion; homopol, homopolymer.
Kerr et al.
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the insert is not in frame with the M009L sequence. Interestingly,
this duplication was observed in the Canberra region in viruses
isolated in 1995 and 1996 and is also present in viruses isolated
from southwest Queensland in 1999; that viruses with this dele-
tion occupy such awide geographic areameans that the deletion is
unlikely to have an adverse effect on fitness. Whether this dupli-
cation of two potential virulence genes increases virulence or
compensates for othermutations by increasing expression of these
proteins is not known.
Finally, two intergenic repeat sequence regions have been de-
fined as being variable in Australian field isolates (25, 31), one
between M017L and M018L, with 2 to 8 extra copies of a GTAT
GTAG repeat compared to SLS and 1 or 2 extra copies of an AGT
TTAGT repeat (Fig. 4A), and the other immediately upstream of
the M002 gene in the TIR, with 27 or 39 nucleotides deleted in 10
recent Australian isolates (Fig. 4B). That the latter duplication
occurs onmultiple branches of the phylogenetic tree indicates that
it has been gained or lost in different viral lineages.
Promoter sequences.Alterations in gene expression and po-
tentially virulence could occur due to changes in promoters.
The poxvirus early (E), intermediate (I), and late (L) promoter
sequences are conserved in the leporipoxviruses (44). Six vi-
ruses have mutations with a potential impact on putative pro-
moters. WS6/346 has a T deletion in the upstream T tract of the
M008.1L/R L promoter (Fig. 5A); OB1/406 has an extra T in the
upstream T tract of the L promoter for M057L (Fig. 5B). G91
has a mutation in a putative weak L promoter for M000.5L/R,
but whether this ORF is expressed has not been determined
(Fig. 5C). SWH/8-2-93 has an extra A inserted in the potential
E promoter for M138L (Fig. 5D), which might be predicted to
enhance the promoter structure based on consensus early pro-
moter sequences (44). WS6/1071 and OB3/1120 have an A de-
leted in the 3= end of the potential E promoter of M153R (Fig.
5E), which could have an impact on promoter activity. How-
ever, both viruses also have a deletion at nt 321 in M153R,
which disrupts the ORF.
Pathways to attenuationandvirulence inAustralian isolates.
Overall, nine viruses derived from SLS and sequenced here have
previously defined virulence phenotypes. The coding changes
from SLS in these viruses are summarized in Table 6. Three atten-
uated viruses were sequenced from the 1990s, of which only the
grade 5 Meby has a probable explanation for its attenuated phe-
notype. Strikingly, the grade 4 SWH/9/1992 is closely related to
the grade 1 BRK. Excluding the disruption of the M036L ORF in
BRK, only three coding differences exist to explain the attenuated
phenotype of SWH: a P227Smutation at the C terminus ofM004,
a P33L mutation in M087 (mRNA capping enzyme; P at this po-
sition is conserved in most poxviruses), and a VP duplication in
the M093 viral core protein. BRK has one unique mutation out-
sideM036, A47V inM112, a Holliday junction resolvase. The A in
this position is not conserved outside the leporipoxviruses. A sim-
ilar analysis with the three grade 1 viruses sequenced revealed only
two shared mutations for two viruses: Bendigo and Wellington
both share I481V in M032 and Y302H in M099, the major core
protein precursor. This suggests that attenuation and virulence
mutations may be subtle or involve multiple epistatic effects.
An example of the complexity of possible virulence determinants
involves two genes that encode proteins that are functionally con-
served in poxviruses and inhibit type 1 interferon responses:M029L,
an orthologue of VACV E3L, and M156R, an orthologue of VACV
K3L (Fig. 1). Eleven of the recent Australian isolates have an A17V
mutation inM029L, the only one in this gene; based on a molecular
clock dating analysis, thismutationwas fixed between 1969 and 1975
(Fig. 1) and coincides with the introduction and spread of the Euro-
pean rabbit flea, which altered the epizootology of myxomatosis in
temperate Australia. Interestingly, this mutated sequence has re-
verted to the original sequence twice on independent branches of the
tree and in viruses isolated fromwidely separated geographic regions.
M029 has been shown to function similarly to VACV E3, binding
double-stranded RNA, inhibiting protein kinase R (PKR) activation,
and inhibiting IFN-, tumor necrosis factor alpha (TNF-), and in-
terleukin-6 (IL-6) expression (45); it is a critical virulence factor in
M009L Δ Insert
Original TIR boundary
M154R
M153L Δ 
M156L
TIRTIR
M153-M156
New TIR boundary
T insert 
frameshi
FIG3 Expansion of the TIR boundaries in SWH/1209,OB2/W60, BD23, andBD24.Duplication of the 1,635-nucleotide region outside the right-hand (RH)TIR
containingM153R toM156R and inversion and insertion of this sequence at the left-hand (LH) TIR are shown. This replaces the 3= 923 nucleotides ofM009L at
the LH end; there are now complete copies of M156 and M154 at each end of the genome, but M153 has lost the 5= 36 nucleotides and promoter at the LH end
of the genome.M156R originally spanned the TIR boundary at the RH end of the genome. The sequence in the TIRwas present at the LH end as noncodingDNA.
Note that the Lu genome annotation does not use the M155 gene number.
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rabbit infections but also has a second function of binding RNA he-
licaseA(RHA;DHX9),whichpromotes virus replication in somecell
lines, so it has been described as a dual-function virulence and host
range factor (46). The amino acid sequence from the related lepo-
ripoxvirus RFV is conserved from amino acid 1 to 8 and is iden-
tical to that from MYXV from amino acid 20 to 55 but is poorly
conserved between residues 9 and 19; this region is also divergent
in the Californian MSW strain of MYXV (47). If we consider the
mutation and reversion in MYXV and the divergence in 3 lepori-
poxviruses with different natural hosts, then we find it possible
that this region is involved in species specificity and host adapta-
tion.
M156 is a homologue of the alpha subunit of eukaryotic
translation initiation factor 2 (eIF2) and competes with eIF2
for phosphorylation by PKR (42). The L98P mutation in M156
is present in 13 of the modern isolates and most likely has
appeared twice on independent branches of the tree (Fig. 1)
(although a lack of bootstrap support at key nodes means that
we cannot formally exclude a single origin of this mutation).
Two of the viruses with this mutation, WS6/346 and OB3/
Y317, which are phylogenetically distinct, possess an additional
T deletion in a homopolymer at the 3= end of M156R that
allows read-through of the stop codon and the addition of EG
at the C terminus of the protein. Based on its nuclear magnetic
resonance (NMR) structure, the 102-amino-acidM156 protein
is predicted to be a 5-stranded antiparallel  barrel (42). The
L98P mutation occurs in the 5 sheet, with the L side chain
predicted to form part of the interior of the barrel, while it has
been proposed that residues D97 and R99 are involved in bind-
ing PKR (42). Interestingly, M156R has been duplicated in the
common ancestor of four of the viruses sequenced here, all of
which have the L98P mutation. In VACV undergoing artificial
selection, K3L has been shown to expand and reduce in copy
numbers while acquiring adaptive mutations (48).
The virulent Lu CSL virus, released in Australia from the
1970s to the 1990s. The Lu virus was widely released in Australia
from the 1970s to the 1990s. However, our phylogenetic analysis,
coupledwith previous studies (25, 31, 49), demonstrates that Aus-
tralian field isolates are derived from SLS and that, if Lu has left
descendant viruses in Australia, they have not been sampled. The
Lu virus sequenced here is from a vial supplied for release and has
only a single difference from the originally published Lu sequence
(12, 34): a C insert at nucleotide 142 in a homopolymer tract in
M127L, causing a frameshift mutation. The mutation may have
been present in a single plaque or pock used to produce the orig-
inal seed virus for release (50).
DISCUSSION
MYXV evolution is characterized by a relatively high rate of nu-
cleotide substitution, frequent changes of virulence, and a rapid
A) Intergenic repeat sequence between M017L and M018L
Lu  (18237) GTATGTAGGTATGTAG--------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA (18263)
SLS (18236) GTATGTAG----------------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA (18254)
GV  GTATGTAG----------------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA
KM13  GTATGTAG----------------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA
Ur  GTATGTAG----------------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA
BRK  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
BEND  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
WELL  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
GUNG  GTATGTAGGTATGTAGGTATGTAGGTATGTAG----------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
SWH  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
Meby  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGT----------------GTAA
BRK/12-2-93 GTATGTAGGTATGTAG--------------------------------------------------------CTTAGTAGTTTAGT----------------GTAA
BRK/897 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
OB1/406 GTATGTAGGTATGTAG--------------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
SWH/1209 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
BD23  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
SWH/8-2-93 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
WS1/234 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
WS1/328 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
WS6/1071 GTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAGCTTAGTAGTTTAGT----------------GTAA
WS6 346 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
BD44  GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
OB2/W60 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGT--------GTAA
OB3/Y317 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
OB3/1120 GTATGTAGGTATGTAGGTATGTAGGTATGTAGGTATGTAG--------------------------------CTTAGTAGTTTAGT----------------GTAA
SWH/805 GTATGTAGGTATGTAGGTATGTAG------------------------------------------------CTTAGTAGTTTAGTAGTTTAGTAGTTTAGTGTAA
B) Intergenic deletions between M002L/R and M003L/R
Lu  (2727) CCGAATTAGAGAGGAGCCAATTAGGAGCCGAATTAGGAGCCGAATTAGAGAGGAGCCGAATTAGGAGCCGAATTAGAGAGGAGCCA (2822)
SLS (2736) CCGAATTAGAGAGGAGCCAATTAGGAGCCGAATTAGGAGCCGAATTAGAGAGGAGCC-AATTAGGAGCCGAATTAGAGAGGAGCCA (2820)
BEND  CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
WELL  CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
GUNG  CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
BRK/807 CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
SWH/8-2-93 CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
WS1/234 CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
SWH/805 CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
OB3/Y317 CCGAATTAGAGAGGAGCCAATTAGGAGCCG----------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
WS6/346 CCGAATTAGAGAGGAGCC----------------------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
OB3/1120 CCGAATTAGAGAGGAGCC----------------------------------------AATTAGGAGCCGAATTAGAGAGGAGCCA
FIG 4 Insertions and deletions in noncoding repeat sequence regions in MYXV isolates.
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spread in geographic space. This was exemplified by the initial
mosquito-borne epizootic in 1950 to 1951, during which SLS
spread across an area approximately 1,600 km south to north and
1,800 km east to west in 3 months (4). Indeed, our phylogeo-
graphic analysis clearly shows that viruses from geographically
disjunct regions ofAustralia can still be remarkably closely related,
indicative of frequent viral traffic. The success ofMYXV and, sub-
sequently, rabbit hemorrhagic disease virus (RHDV) as biological
controls, combined with changes in land management, means
that modern rabbit populations are likely to be less connected
than in 1950 (51, 52). The key vectors for viral transmission are the
mosquito, which is predominantly a spring to autumn vector and
requires water for breeding, and rabbit fleas, Spilopsyllus cuniculi
(in temperate Australia) and Xenopsylla cunicularis (in arid Aus-
tralia), which were introduced into Australia in 1970 and 1994,
respectively. Fleas provide the potential for local transmission year
round, whereasmosquitoes are seasonal but have the potential for
longer-distance spread. Virus may also be spread by dispersing
migrating rabbits—predominantly juvenile males—that are ei-
ther incubating the disease or immune and carrying fleas with the
virus. In addition, large-scale rabbitmigrations out of dry country
during droughts may bring high numbers of susceptible animals
into contact with virus, providing opportunities for spread. Acci-
dental or deliberate translocation of infected rabbits could possi-
bly also occur. Work in the Canberra district also suggests that
viral spread is rapid, as shown by the multiple viral lineages that
can cocirculate within a single community, with no apparent
dominance of one lineage over any other. Such lineage cocircula-
tion also tentatively suggests that these viruses do not differ greatly
in long-term fitness despite their possible differences in virulence,
although this will need to be confirmed with additional data. In-
deed, in our analysis as a whole, there was no obvious signal for
major fitness differences across multiple genotypes within a small
geographic range.
The outcome of infection withMYXV depends on the interac-
tion of multiple viral immune evasion and immunosuppression
proteins and proteins and cells of the host innate and adaptive
immune systems, together with the proteins required for virus
replication, assembly, and infection. The emergence of slightly
attenuated viruses during the early radiation in Australia and Eu-
rope means that mutations that enhanced transmission were se-
lected because the infected rabbit survived longer than rabbits
infected with grade 1 strains.
Most of these early (slightly) attenuated viruses still had case
fatality rates of 90 to 99%, but with prolonged survival times com-
pared to those for SLS and Lu (6, 9, 53). Experimentally, grade 4
viruses (case fatality rate of 50 to 70%; average survival times of 29
to 50 days) had the highest rates of mosquito transmission (10),
but in field surveys from 1951 to 1981, these viruses were always
less prevalent than grade 3 viruses (54). The rapid selection of
rabbits with resistance to myxomatosis, which appears to operate
through an enhanced innate immune response rather than resis-
tance to infection (55, 56), is likely to have driven virus evolution
toward increased virulence and hence tomaintain transmissibility
and competitiveness, and this may explain the preponderance of
grade 3 viruses since all these virulence measurements were done
in laboratory rabbits with no resistance. Viruses with a grade 1
phenotype in laboratory rabbits appear as grade 4 or 5 in wild
rabbits with genetic resistance, while some such as BRK are found
to be more virulent than the progenitor SLS when tested in wild
rabbits (57, 58).
The pathway to virulence reversion and enhancement could
involve reversal of attenuatingmutations. For example, reversal of
the indel inM083L has occurred in the common ancestor to all the
modern isolates that we sequenced, while that inM014Lwas com-
mon to all three early viruses sequenced, although whether this is
a reversal is not clear. Similarly, mutations could compensate for
attenuating mutations, such as the disruption of M036L, which
5’ TGCGACGTTTTTTTTGAGGGTTAAATGA 3’
5’ TTTTTTTTGTGATAAATG 3’
5’ ATTCTACGCGGACCTCCATGG 3’
5’ GTAGACTAAAACAC-AAAAAAAATCTTGCTTCTGCGATATG 3’
5’ CTTTTTGTTTATGGGGAAACTCTAAAAAAAATTGTCAATTAAAGTAAATAGGTTGTGTAAACATG 3’
A) M008.1L/R late promoter
B) M057L late promoter
C) M000.5L/R possible late promoter
D) M138L early promoter
E) M153R early promoter
FIG 5 Sequence mutations in 5 potential promoter regions. (A)M008.1L/R late promoter. There is a TAAAT late promoter motif (italicized) incorporating the
ATG start codon (in red). This is preceded by a 6-nt spacer and then a run of 8 Ts (underlined), which is typical of strong late promoters (spacer of 4 to 10 nt and
then a T-rich tract of 5 to 15 nt). A number of isolates have a mutation at the underlined upstream T (T¡C), but this seems unlikely to affect the promoter
structure. WS6 346 and OBY317 have a T deletion in the 8-T tract. At the LH end of the genome this promoter is in a noncoding sequence, but at the RH end it
is within the 3= end of M156R. (B) M057L late promoter. A TAAAT motif incorporates the ATG, a 4-nucleotide spacer, and then 8 Ts. OB1/406 has an extra T
in the T tract, making 9 Ts. (C)M000.5L/R possible late promoter. The putative promoter structure is italicized. The 2 C residues are almost invariably A in late
promoters. There is no upstream T-rich domain for 100 nt upstream. G-91 has a C¡T mutation in the putative promoter structure, yielding TTCATG. There
is no sign of an upstream A-rich region that could act as an early promoter. (D) M138L early promoter. SWH 8/2/93 has an extra A. The dash is in the poly(A)
tract of the italicized potential promoter. (E)M153R early promoter. A potential early promoter sequence is italicized. All Australian isolates lack the upstream
T (underlined). This seems unlikely to have any impact on the promoter. WS6 1071 and OB31120 lack an A in the homopolymer tract (boldface). A possible
alternative promoter is underlined but seems too close to the ATG.
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appears to be attenuating in Sussex but not in BRK, or mutations
could increase virulence by new pathways. The duplication of vir-
ulence genes and the fragmentation of some reading frames also
provide the rawmaterial for further evolution of new functions, as
has occurred, for example, in cowpox virus, where a gene frag-
ment has evolved a new function in immunosuppression (59).
While thismight suggest that field isolates should nowbe of higher
virulence for laboratory rabbits, the reality appearsmore nuanced,
with grade 4 and 5 viruses present in our samples, indicating that
many factors at the local level influence the effective virulence and
successful transmission. In addition, the widespread establish-
ment of the European rabbit flea in Australia, which was credited
with enhancing the impact of myxomatosis by providing a year-
round vector and increasing transmission, may have altered the
selection pressures on both virus and rabbit.
The large and complex genome of MYXV has provided the
plasticity for multiple routes to attenuation and multiple and
complex routes back to virulence. The accumulation ofmutations
in more-recent virus isolates makes it difficult to identify single
mutations that are critical for phenotype, whether virulent or at-
tenuated. In particular, we have shown here that it is difficult to
define possible roles for single amino acid changes or potentially
even synonymous changes in this evolutionary process. Indeed,
there has been remarkably little characterization of Australian
field viruses in rabbits or even in cell culture since the 1980s. Im-
portantly, characterization of the sequenced viruses in rabbits will
provide opportunities for matching virulent and attenuated vi-
ruses that are phylogenetically closely related and for using reverse
genetics to define these pathways.
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